Quality control report of the Hypertension Center(2024)
10.3969/j.issn.1004-8812.2025.09.002
- VernacularTitle:高血压达标中心质控报告(2024)
- Author:
Ning-ling SUN
- Collective Name:Hypertension Center Expert Committee,China Heart House
- Publication Type:Journal Article
- Keywords:
Hypertension;
Hypertension Center;
Chronic disease management;
Control rate/Achievement rate;
Follow-up;
Single-pill combination
- From:
Chinese Journal of Interventional Cardiology
2025;33(9):491-499
- CountryChina
- Language:Chinese
-
Abstract:
Hypertension is the most common chronic disease and can lead to severe complications such as stroke,heart disease,and kidney failure.The goal of establishing the Hypertension Center is to standardize the diagnosis and treatment of hypertension,improve the control rate among patients,and benefit more individuals.Based on a systematic evaluation of data reporting quality from the Hypertension Center up to December 31,2024,the hypertension control rate reached 81.27％by the end of 2024,marking a 28.33％increase compared to the initial phase of the center's establishment in 2019.A total of 745 911 patients(83.26％)remain under follow-up management.Cardiovascular risk factors among hypertensive patients in both northern and southern China have been significantly controlled.Regarding target organ damage,the detection rates for urinary albumin-to-creatinine ratio(indicating renal impairment)and estimated glomerular filtration rate(eGFR)improved significantly following the intensive management during the 2024"Kidney Protection Year"slowing the progression of kidney disease.The proportion of combination antihypertensive drug therapies increased from 54.89％initially to 57.19％,with the use of single-pill combination(SPC)rising from 25.98％to 29.68％.It is important to note that follow-up assessments for hypertension-related target organ damage should be further strengthened to enable timely adjustments and optimization of treatment plans for affected patients.
